c10c-G1V3

c10c-G1V3 (1.5625-100 μg/mL; 60 s association, 120 s dissociation) binds to purified human BRAG2 (AA390-763) with a K_d value of 7.37 μM^[1].
c10c-G1V3 (10 μM; 24 h) shows no cytotoxicity against HT22 cells^[1].
c10c-G1V3 (0.1-10 μM; 24 h preincubation prior to OGD injury) protects HT22 cells against OGD-induced damage in a dose-dependent manner^[1].
c10c-G1V3 (20 μM; 4 h) exhibits stronger membrane permeability than the unmodified 3Y peptide scaffold in HEK293T cells^[1].
c10c-G1V3 (200 μM; 0-8 h) exhibits superior plasma stability in rat plasma, with a half-life >8 h^[1].
c10c-G1V3 (0.1-10 μM; preincubated for 2 h prior to exposure to 5 mM glutamate for 24 h) protects HT22 cells against glutamate-induced excitotoxicity, maintaining a cell viability rate of 76.34% at high concentrations^[1].
c10c-G1V3 (10 μM; 30 min preincubation prior to exposure to 5 mM glutamate for 24 h) significantly inhibits glutamate-induced ROS accumulation and alleviates intracellular oxidative stress in HT22 cells^[1].
c10c-G1V3 (10 μM; preincubated for 2 h prior to exposure to 10 mM glutamate for 24 h) reduces glutamate-induced apoptosis of HT22 cells^[1].
c10c-G1V3 (10 μM; preincubated for 2 h prior to exposure to 10 mM glutamate for 24 h) regulates the mitochondrial apoptosis pathway in HT22 cells, and alleviates glutamate-induced apoptosis by upregulating the expression of the anti-apoptotic protein Bcl-2 and downregulating the expression of the pro-apoptotic protein Bax and cleaved-caspase 3^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.